ONCOTHERAPY SCIENCE INC.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, … Read more
ONCOTHERAPY SCIENCE INC. (30O) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONCOTHERAPY SCIENCE INC. (30O) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONCOTHERAPY SCIENCE INC. - Net Assets Trend (None–None)
This chart illustrates how ONCOTHERAPY SCIENCE INC.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONCOTHERAPY SCIENCE INC. (None–None)
The table below shows the annual net assets of ONCOTHERAPY SCIENCE INC. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONCOTHERAPY SCIENCE INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONCOTHERAPY SCIENCE INC. Competitors by Market Cap
The table below lists competitors of ONCOTHERAPY SCIENCE INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
$32.65 Million |
|
JF Technology BHD
KLSE:0146
|
$32.65 Million |
|
FnGuide Inc.
KQ:064850
|
$32.66 Million |
|
Falcon's Beyond Global, Inc. Class A Common Stock
NASDAQ:FBYD
|
$32.66 Million |
|
All Cosmos Bio-Tech Holding Corp
TW:4148
|
$32.62 Million |
|
GIIR Inc
KO:035000
|
$32.62 Million |
|
Helios Energy Limited
PINK:HLEGF
|
$32.60 Million |
|
Vicapsys Life Sciences Inc
PINK:VICP
|
$32.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONCOTHERAPY SCIENCE INC.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONCOTHERAPY SCIENCE INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONCOTHERAPY SCIENCE INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONCOTHERAPY SCIENCE INC.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONCOTHERAPY SCIENCE INC. (30O) | €- | N/A | N/A | $32.63 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |